Meaningful outcomes

Clinical validation is the foundation of Woebot Health. In collaboration with some of the world’s leading research institutions and groups, including Stanford University and the National Institutes of Drug Abuse, we continuously test efficacy using psychometrically validated efficacy measures, including PHQ 9 and 2, GAD 7 and 2 and EPDS.

Using Woebot leads to measurable reductions in anxiety and depression

In a study conducted at Stanford University comparing Woebot to a control group, the results showed that using Woebot led to significant reductions in anxiety and depression among people aged 18-28 years old.

The group using Woebot saw reduced symptoms of anxiety and depression over the study period as measured by the PHQ-9 (F=6.47; P=.01), while those in the information control group did not. During the study, 85% of the experimental group interacted with Woebot on a daily or almost daily basis, even though no set amount of time had been prescribed.

A second Stanford-based study conducted with 400 participants observed depression and anxiety outcomes among a group of Woebot users. Among its findings: after four weeks, participants who used Woebot showed a 32% reduction in depression as defined by the PHQ-9 and a 38% reduction in anxiety as defined by the GAD-7.

In collaboration with Lucile Packard’s Childrens Hospital at Stanford University, we conducted an RCT to evaluate acceptability and satisfaction with Woebot as a postpartum mood management tool. Women (N=192) were recruited and randomized to the chatbot intervention or treatment as usual during their delivery hospitalization. Participants reported both high satisfaction with and acceptability of the 6-week program.

Research awards

The National Institutes of Drug Abuse (NIDA), one of 27 institutes and centers that comprise the National Institutes of Health (NIH), has awarded Woebot Health research grants to study their products among adults with substance use disorder.

Conducted in collaboration with Stanford University’s School of Medicine, the grant covers:

  • A NIDA Small Business Innovation Research Award supporting a two-part study: Phase 1 (N=104) is a non-controlled pilot study to evaluate the feasibility and acceptability of Woebot; Phase II will investigate Woebot’s efficacy compared to an active control condition in a fully-powered randomized clinical trial (N=206).
  • Experts expect Covid-19’s direct and indirect impact upon individuals with substance use disorders to be particularly heavy. In a Covid-19 Administrative Supplement to the Parent Grant Small Business Innovation Research Award, NIDA is helping Woebot expand understanding of Woebot’s efficacy while investigating Covid-19’s impact upon the adults with substance use disorder.

See a complete list of peer reviewed manuscripts, abstracts, posters, manuscripts in progress and research awards in The Woebot Health’s Research Bibliography.